This is a package of 90 tablets of Dialyvite Supreme D Ascorbic Acid, Cholecalciferol, Alpha-Tocopherol, Thiamine, Riboflavin, Niacinamide, Pyridoxine, Folic Acid, Cobalamin, Biotin, Pantothenic Acid, Zinc, Selenium 100 mg; 2000 [iU]/1; 30 [iU]/1; 1.5 mg; 1.7 mg; 20 mg; 25 mg; 3 mg; 1 mg; 300 ug/ Tablet, Coated from Hillestad Pharmaceuticals USA, no longer marketed (first marketed Sep 2010), no longer in the FDA NDC Directory, this package's marketing ended Oct 2026; retail pharmacies pay about $0.3479 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
🏷️ FDA NDC (as labeled)10542-009-09billing pads the product segment with a zero
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy
NDC database record
One package, one record: these facts belong to NDC 10542-009-09 alone.
Record
FDA NDC Directory package listing · Human prescription drug
Code segments
10542 labeler · 009 product · 09 package
Package marketed since
Sep 8, 2010
Package marketing ended
Oct 31, 2026
Sample package
No — commercial package
Billing quantity
90 EA per package
Barcode (UPC)
0105420090904
Medicaid fills, this package
75 prescriptions in the last four reported quarters
FDA record last changed
Nov 1, 2026
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Oct 2026. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)10542-009-09
Product NDC10542-009
11-digit billing NDC10542000909
NCPDP billing unitEA — each (per item)
UNIIPQ6CK8PD0R, 1C6V77QF41, LU4B53JYVE, 8K0I04919X, TLM2976OFR, 25X51I8RD4 +7 more
UPC0105420090904
SPL Set ID46fc3acf-1e6d-4830-ae9a-abd9c1132fca
Established class (EPC)Vitamin C; Vitamin D
Chemical classAscorbic Acid; Vitamin D
DEA scheduleNon-controlled
Marketing categoryUNAPPROVED DRUG OTHER
Marketing statusDiscontinued
FDA listing statusDiscontinued by firm (certified through Oct 2026)
Therapeutic class — broad (HIC1)Electrolyte Balance/Metabolism/Nutrition
HIC2 codeC6
Therapeutic class — intermediate (HIC2)Vitamins
HIC3 codeC6B
Therapeutic class — specific (HIC3)Vitamin B Preparations
AHFS code88:08.00.00
AHFS classVitamin B Complex
FDB label nameDIALYVITE SUPREME D TABLET
FDB brand nameDialyvite Supreme D
Legend statusQ — Non-drug — dietary supplement, vitamin, medical food, or herbal preparation
Quick answers
GSN (GCN sequence number):066863
GCN:29275
GPI-14 (Medi-Span):78310000000300
HICL (First Databank):037275
AHFS class code:88:08.00.00
Why two NDCs?
The FDA registers this code as 10542-009-09 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 10542-0009-09. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
First Databank (licensed)
· refreshed Nov 19, 2026
Clinical
Label name DIALYVITE SUPREME D TABLETIngredient Multivitamin-Minerals No.25/Folic Acid/Vitamin D3
🧪 What is this product?
Dialyvite Supreme D is a coated tablet taken by mouth that contains a combination of vitamins and minerals. The product includes vitamin C (ascorbic acid), vitamin D (cholecalciferol), vitamin E (alpha-tocopherol), and several B vitamins (thiamine, riboflavin, niacinamide, pyridoxine, folic acid, cobalamin, and biotin), along with pantothenic acid, zinc, and selenium. These ingredients are commonly used as nutritional supplements to help address vitamin and mineral deficiencies. This product is marketed without an approved FDA application.
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per ea
Per package
Retail pharmacies payNADAC · weekly
$0.348
$31.31 / 90 tablets
Medicaid paysCMS SDUD · 12 mo
$0.5670
$51.03 / 90 tablets
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Flat over the last 14 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
You're viewing the largest of 2 pack sizes for this product.
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
This is a 90-count package — 90 tablet, coated in 1 bottle, plastic.
How does this package differ from NDC 10542-0009-02?
Both are Dialyvite Supreme D Ascorbic Acid, Cholecalciferol, Alpha-Tocopherol, Thiamine, Riboflavin, Niacinamide, Pyridoxine, Folic Acid, Cobalamin, Biotin, Pantothenic Acid, Zinc, Selenium 100 mg; 2000 [iU]/1; 30 [iU]/1; 1.5 mg; 1.7 mg; 20 mg; 25 mg; 3 mg; 1 mg; 300 ug/ Tablet, Coated — the drug itself is identical. This page's package is the 90-count one, while NDC 10542-0009-02 is the 7 tablets package.
What NDC number is used to bill for this package of Dialyvite Supreme D Ascorbic Acid, Cholecalciferol, Alpha-Tocopherol, Thiamine, Riboflavin, Niacinamide, Pyridoxine, Folic Acid, Cobalamin, Biotin, Pantothenic Acid, Zinc, Selenium 100 mg; 2000 [iU]/1; 30 [iU]/1; 1.5 mg; 1.7 mg; 20 mg; 25 mg; 3 mg; 1 mg; 300 ug/ Tablet, Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerHillestad Pharmaceuticals USA
Labeler code10542
First marketedSep 2010
Product typeHuman Prescription Drug
Portfolio5 products on file
More NDCs from Hillestad Pharmaceuticals USA labeler code 10542
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
INDICATIONS AND USAGE Dialyvite Supreme D is a prescription folic acid supplement with additional nutrients indicated for use in improving the nutritional status of renal dialysis patients.
⏱️Dosage and Administration13 words▾
DOSAGE AND ADMINISTRATION Take one tablet or as directed by your physician, orally.
⛔Contraindications15 words▾
CONTRAINDICATIONS This product is contraindicated in patients with known hypersensitivity to any of the ingredients.
🤒Adverse Reactions22 words▾
ADVERSE REACTIONS Allergic sensitizations have been reported following oral administration of folic acid. Consult your physician immediately if adverse side effects occur.
📋Description112 words▾
DESCRIPTION Dialyvite Supreme D is a prescription folic acid supplement with additional nutrients for kidney dialysis patients. Dialyvite Supreme D is a small, round, light green, coated tablet, with debossed "H" on one side, and bisected on the other side. Each tablet contains: Folic Acid.....3 mg Vitamin C (Ascorbic Acid).....100 mg Vitamin D (Cholecalciferol).....2000 IU Vitamin E (D-alpha-Tocopheryl Acid Succinate).....30 IU Thiamine Mononitrate.....1.5 mg Riboflavin.....1.7 mg Niacinamide.....20 mg Vitamin B6 (Pyridoxine HCl).....25 mg Vitamin B12 (Methylcobalamin).....1 mg Biotin.....300 mcg Pantothenic Acid (Calcium Pantothenate).....10 mg Zinc (Zinc Citrate).....15 mg Selenium (Selenium Amino Acid Chelate).....70 mcg Inactive ingredients: Microcrystalline Cellulose, Croscarmellose Sodium, Mono- and Diglycerides, Pharmaceutical Glaze, Starch, Silicon Dioxide, Calcium Stearate, Chlorophyllin (color).
⚠️Precautions24 words▾
PRECAUTIONS Folic acid supplementation may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations progress. Keep out of reach of children.
📄Package Label / Principal Display Panel19 words▾
PRINCIPAL DISPLAY PANEL NDC 10542-009-09 Dialyvite Supreme D Multivitamin Supplement for Dialysis Patients 90 Tablets Dialyvite Supreme D PDP
No label section mentions that — try another word, or open the full label on DailyMed below.
Glossary — plain-language definitions of medical terms used in this label:
contraindicated: Should not be used in that situation, because the risk is considered too high.
Adverse Reactions: Unwanted or harmful effects that people experienced while taking a medicine, listed on its official label.
anemia: A low level of red blood cells or the oxygen-carrying protein inside them, which can cause tiredness, weakness, and paleness.
Contraindications: A list of situations or health conditions in which a medicine should not be used because the chance of harm is too high.
Dosage and Administration: The label section explaining how much of a medicine to use and how to take or give it.
hypersensitivity: An overreaction of the body's defense system to a substance, causing symptoms such as rash, swelling, or trouble breathing.
Indications and Usage: The label section stating which medical conditions the FDA has officially approved the medicine to treat, prevent, or manage.
NDC: A unique number that identifies a specific medicine, its maker, strength, and package size.
remission: A period when the signs and symptoms of cancer are reduced or have disappeared.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
75
Units reimbursed last 4 qtrs
2.9K
Gross reimbursed last 4 qtrs
$1.6K
Avg / prescription
$21.70
Avg / unit
$0.5670
Latest quarter Q1 2026
14Rx
Medicaid pays / ea
$0.5670
gross reimbursed
vs
NADAC / ea
$0.3479
acquisition cost
=
Spread
+$0.2191
+63% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS60% MCO
Fee-for-service · 30 Rx Managed care · 45 Rx
State Medicaid map
Units reimbursed · per 100k residents
3.814.1
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1Ohio14.1 /100k
2Missouri13.4 /100k
3Michigan3.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 201 Rx · 7,125 units · $3,836 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Dialyvite Supreme D (this brand).
Top reported reactions
Death2
Chest Discomfort1
Diarrhoea1
Pancytopenia1
Stomatitis1
Throat Tightness1
Treatment Noncompliance1
Reporter sex
Male · 20%
Female · 80%
Serious outcomes
Death2
Disabling1
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
Finished prescription productMarketed without an FDA applicationNo longer marketed (per FDA listing data)
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes)
✓ Available
Labeler
✓ Available
Product & package description
✓ Available
Marketing category & status
✓ Available
Active ingredient / dosage form / route
✓ Available
FDA label (SPL via DailyMed)
✓ Available
Package photos
— Not published for this NDCNo photo available yet for this listing.
Inactive ingredients (structured)
— Not published for this NDCThe labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS)
✓ Available
Orange Book / therapeutic-equivalence data
— Not published for this NDCApplies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk
— Not published for this NDCMost self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD)
✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 7 tablets (10542-0009-02). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Hillestad Pharmaceuticals USA is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.